Vor Biopharma Inc (VOR)

$1.91 +0.46 (31.72%)
Market Cap 238.67M
Revenue (ttm) 0.00
Net Income (ttm) -116.91M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 24,491,799
Avg Vol 18,601,596
Day's Range N/A - N/A
Shares Out 124.96M
Stochastic %K 93%
Beta 2.04
Analysts Sell
Price Target $1.18

Company Profile

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other blood cancers; trem-cel in combination with Mylotarg to...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 655 6580
Address:
100 Cambridgepark Drive, Suite 101, Cambridge, United States
FickleFin
FickleFin Jul. 7 at 11:14 AM
$VOR on the go since .16 cents... 📈 $PSTV needs that kickstart. 📉
0 · Reply
blackpearl1
blackpearl1 Jul. 7 at 10:50 AM
$WOLF $VOR has a better chance of options gains imo.
0 · Reply
blackpearl1
blackpearl1 Jul. 7 at 10:42 AM
$IPA $VOR is a champ baby! LFG!!!
0 · Reply
blackpearl1
blackpearl1 Jul. 7 at 10:14 AM
$VOR Already pumping baby!
0 · Reply
VSWeWork
VSWeWork Jul. 7 at 9:50 AM
$MIRA is the next $VOR ⚡️⚡️⚡️
1 · Reply
TALENT_ON_LOAN_FROM_GOD
TALENT_ON_LOAN_FROM_GOD Jul. 7 at 9:50 AM
$BMNR $MIRA $VOR $WOLF MIRA GET ON IT $TSLA SHORT MONEYMADE
0 · Reply
Paraplego
Paraplego Jul. 7 at 9:31 AM
$VOR after soo many positive news this can only grow up to 15 usd how much will it grow this week
1 · Reply
LFG2030
LFG2030 Jul. 7 at 9:28 AM
$VOR wow lets goo
0 · Reply
Wilsonscotten
Wilsonscotten Jul. 7 at 5:02 AM
$VOR I got the powerrrr
0 · Reply
KevMomentum
KevMomentum Jul. 7 at 3:21 AM
$VOR textbook continuation set up here, multiple high rVol days here and showing no signs of slowing down… I’ll be eyeing this to pivot OVER double top/trend resistance, for the next leg higher into our daily ranges Range to $2.50+
0 · Reply
Latest News on VOR
Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 1, 2025, 4:00 PM EDT - 5 days ago

Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune Market

Jun 30, 2025, 2:31 PM EDT - 6 days ago

Vor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune Market

Vor Bio Announces $175 Million Private Placement

Jun 25, 2025, 4:50 PM EDT - 11 days ago

Vor Bio Announces $175 Million Private Placement

Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset

Jun 25, 2025, 4:45 PM EDT - 11 days ago

Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

May 8, 2025, 8:30 AM EDT - 2 months ago

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

Mar 20, 2025, 4:05 PM EDT - 3 months ago

Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials

Feb 13, 2025, 8:00 AM EST - 5 months ago

Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials

Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Feb 3, 2025, 8:00 AM EST - 5 months ago

Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

Jan 8, 2025, 9:00 AM EST - 6 months ago

Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

Vor Bio Announces $55.6 Million Private Placement

Dec 27, 2024, 9:00 AM EST - 6 months ago

Vor Bio Announces $55.6 Million Private Placement

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

Dec 9, 2024, 7:30 AM EST - 7 months ago

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer

Sep 30, 2024, 7:00 AM EDT - 10 months ago

Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer

What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday?

Sep 6, 2024, 9:35 AM EDT - 10 months ago

What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday?

New Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted Therapies

Sep 5, 2024, 4:01 PM EDT - 10 months ago

New Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted Therapies

Vor Bio to Participate in Upcoming Investor Conferences

Aug 28, 2024, 8:00 AM EDT - 11 months ago

Vor Bio to Participate in Upcoming Investor Conferences

Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update

Aug 8, 2024, 4:05 PM EDT - 11 months ago

Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Aug 2, 2024, 4:01 PM EDT - 1 year ago

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update

May 9, 2024, 4:05 PM EDT - 1 year ago

Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update

Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors

May 2, 2024, 4:01 PM EDT - 1 year ago

Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors

Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Mar 20, 2024, 4:05 PM EDT - 1 year ago

Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 7, 2024, 8:00 AM EST - 1 year ago

Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update

Jan 17, 2024, 4:01 PM EST - 1 year ago

Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update

Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit

Nov 27, 2023, 8:00 AM EST - 1 year ago

Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit

Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference

Nov 9, 2023, 4:01 PM EST - 1 year ago

Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference

Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update

Nov 7, 2023, 4:05 PM EST - 1 year ago

Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update

Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio's Novel eHSC and CAR-T Platform

Nov 2, 2023, 9:01 AM EDT - 1 year ago

Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio's Novel eHSC and CAR-T Platform

Vor Bio Reports Second Quarter 2023 Financial Results and Provides Company Update

Aug 10, 2023, 4:05 PM EDT - 2 years ago

Vor Bio Reports Second Quarter 2023 Financial Results and Provides Company Update

Vor Bio to Participate in the Wedbush PacGrow Healthcare Conference

Aug 1, 2023, 8:00 AM EDT - 2 years ago

Vor Bio to Participate in the Wedbush PacGrow Healthcare Conference

Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In July - Cibus (NASDAQ:CBUS), Bellerophon Therapeutics (NASDAQ:BLPH)

Jul 5, 2023, 8:51 AM EDT - 2 years ago

Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In July - Cibus (NASDAQ:CBUS), Bellerophon Therapeutics (NASDAQ:BLPH)

CBUS LUCY

Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio's Platform

Jun 9, 2023, 7:30 AM EDT - 2 years ago

Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio's Platform

Vor Bio to Participate in the Goldman Sachs Healthcare Conference

Jun 5, 2023, 8:00 AM EDT - 2 years ago

Vor Bio to Participate in the Goldman Sachs Healthcare Conference

Vor Bio Reports First Quarter 2023 Financial Results and Provides Company Update

May 11, 2023, 4:05 PM EDT - 2 years ago

Vor Bio Reports First Quarter 2023 Financial Results and Provides Company Update

Vor Biopharma: Very Interesting Idea For Improving CAR-T Through Stem Cells

Mar 27, 2023, 3:13 PM EDT - 2 years ago

Vor Biopharma: Very Interesting Idea For Improving CAR-T Through Stem Cells

Vor Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update

Mar 23, 2023, 4:01 PM EDT - 2 years ago

Vor Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update

First AML Patient Transplanted with Vor Bio's Trem-cel Demonstrated Durable Engraftment through Multiple Mylotarg™ Cycles at Initial Dose Level

Feb 16, 2023, 12:00 PM EST - 2 years ago

First AML Patient Transplanted with Vor Bio's Trem-cel Demonstrated Durable Engraftment through Multiple Mylotarg™ Cycles at Initial Dose Level

Vor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem Meetings

Jan 19, 2023, 8:00 AM EST - 2 years ago

Vor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem Meetings

Vor Bio to Present at B. Riley Securities' 3rd Annual Oncology Conference

Jan 12, 2023, 8:00 AM EST - 2 years ago

Vor Bio to Present at B. Riley Securities' 3rd Annual Oncology Conference

Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million

Dec 7, 2022, 7:45 AM EST - 2 years ago

Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million

First AML Patient Successfully Transplanted with Vor Bio's Investigational Trem-cel (VOR33) and Tolerated Mylotarg™

Dec 7, 2022, 7:30 AM EST - 2 years ago

First AML Patient Successfully Transplanted with Vor Bio's Investigational Trem-cel (VOR33) and Tolerated Mylotarg™

Vor Bio Reports Third Quarter 2022 Financial Results and Provides Company Update

Nov 10, 2022, 4:15 PM EST - 2 years ago

Vor Bio Reports Third Quarter 2022 Financial Results and Provides Company Update

Vor Bio Appoints Eyal C. Attar, M.D.

Oct 12, 2022, 8:00 AM EDT - 2 years ago

Vor Bio Appoints Eyal C. Attar, M.D.

Vor Bio Demonstrates Potential of Base and Sequential Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment

Oct 11, 2022, 8:00 AM EDT - 2 years ago

Vor Bio Demonstrates Potential of Base and Sequential Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment

Vor Bio Initiates In-house Clinical Manufacturing at Cambridge, MA Headquarters

Sep 28, 2022, 8:00 AM EDT - 3 years ago

Vor Bio Initiates In-house Clinical Manufacturing at Cambridge, MA Headquarters

Vor Bio Reports Second Quarter 2022 Financial Results and Provides Company Update

Aug 11, 2022, 4:15 PM EDT - 3 years ago

Vor Bio Reports Second Quarter 2022 Financial Results and Provides Company Update

Vor Bio Successfully Demonstrates Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment Presented at EHA

Jun 10, 2022, 8:00 AM EDT - 3 years ago

Vor Bio Successfully Demonstrates Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment Presented at EHA

Vor Bio Reports First Quarter 2022 Financial Results and Provides Company Update

May 12, 2022, 4:15 PM EDT - 3 years ago

Vor Bio Reports First Quarter 2022 Financial Results and Provides Company Update

Vor to Participate in Two Upcoming Investor Conferences

May 5, 2022, 8:00 AM EDT - 3 years ago

Vor to Participate in Two Upcoming Investor Conferences

Vor Bio to Present at Keystone Symposia Precision Genome Engineering Meeting

Apr 25, 2022, 8:00 AM EDT - 3 years ago

Vor Bio to Present at Keystone Symposia Precision Genome Engineering Meeting

Vor Bio Announces Retirement of Chief Medical Officer

Apr 14, 2022, 4:15 PM EDT - 3 years ago

Vor Bio Announces Retirement of Chief Medical Officer

Akron BioProducts and Vor Bio to Collaborate on the Development and cGMP Manufacture of Nucleases

Mar 22, 2022, 10:10 AM EDT - 3 years ago

Akron BioProducts and Vor Bio to Collaborate on the Development and cGMP Manufacture of Nucleases

FickleFin
FickleFin Jul. 7 at 11:14 AM
$VOR on the go since .16 cents... 📈 $PSTV needs that kickstart. 📉
0 · Reply
blackpearl1
blackpearl1 Jul. 7 at 10:50 AM
$WOLF $VOR has a better chance of options gains imo.
0 · Reply
blackpearl1
blackpearl1 Jul. 7 at 10:42 AM
$IPA $VOR is a champ baby! LFG!!!
0 · Reply
blackpearl1
blackpearl1 Jul. 7 at 10:14 AM
$VOR Already pumping baby!
0 · Reply
VSWeWork
VSWeWork Jul. 7 at 9:50 AM
$MIRA is the next $VOR ⚡️⚡️⚡️
1 · Reply
TALENT_ON_LOAN_FROM_GOD
TALENT_ON_LOAN_FROM_GOD Jul. 7 at 9:50 AM
$BMNR $MIRA $VOR $WOLF MIRA GET ON IT $TSLA SHORT MONEYMADE
0 · Reply
Paraplego
Paraplego Jul. 7 at 9:31 AM
$VOR after soo many positive news this can only grow up to 15 usd how much will it grow this week
1 · Reply
LFG2030
LFG2030 Jul. 7 at 9:28 AM
$VOR wow lets goo
0 · Reply
Wilsonscotten
Wilsonscotten Jul. 7 at 5:02 AM
$VOR I got the powerrrr
0 · Reply
KevMomentum
KevMomentum Jul. 7 at 3:21 AM
$VOR textbook continuation set up here, multiple high rVol days here and showing no signs of slowing down… I’ll be eyeing this to pivot OVER double top/trend resistance, for the next leg higher into our daily ranges Range to $2.50+
0 · Reply
TALENT_ON_LOAN_FROM_GOD
TALENT_ON_LOAN_FROM_GOD Jul. 7 at 2:56 AM
$MIRA $60M REASONS TO LOAD UP UNDER $5 $BMNR $WOLF $VOR MONEYMADE $TSL short no worries https://finance.yahoo.com/news/mira-pharmaceuticals-announces-board-approval-120000697.html
0 · Reply
FickleFin
FickleFin Jul. 7 at 1:46 AM
$VOR $PSTV LFG ✅
0 · Reply
blackpearl1
blackpearl1 Jul. 7 at 1:29 AM
$VOR $3.00 open?
0 · Reply
PoPPoP26
PoPPoP26 Jul. 6 at 9:02 PM
$GRYP $VOR $WINT 🚀 🚀🚀🚀🚀🚀🚀 tomorrow. Longhauls here.
0 · Reply
TALENT_ON_LOAN_FROM_GOD
TALENT_ON_LOAN_FROM_GOD Jul. 6 at 3:09 PM
$MIRA I KNOW YOU’VE SEEN THE COMMERCIAL “WEGOVY” ON TV A THOUSAND TIMES. HERE IS THE MARKET BREAKDOWN: INJECTABLE VS ORALS NOT INCLUDED: 🤌🤓 $AEBI $VOR $BMNR $WOLF —MONEYMADE SKNY-1 by MIRA market $150B Ozempic (Semaglutide) Mounjaro (tirzepatide) Wegovy (semaglutide) Trulicity (dulaglutide) Zepbound (tirzepatide) SKNY-1 (MAOB-inhibitor) Article on MAO-B inhibitor/weight loss https://neurosciencenews.com/obesity-astrocytes-neuropharmacology-23852/
1 · Reply
Stock_Catcher
Stock_Catcher Jul. 6 at 3:01 PM
Money Monday Watchlist Pt. 2 $RGC $WOLF $LIXT $VOR $CMND
0 · Reply
dbr_island
dbr_island Jul. 6 at 2:15 AM
Can’t wait for Monday! If you’re reading this just know that there are opportunities to make LIFE CHANGING gains EVERY DAY Bull market, Bear market… it doesn’t matter This market lately is designed to have 100% runners almost consistently You just need to know how to play the game and be in the know BEFORE the crowd Been doing this for over 20 years so I understand market behavior Now I may not get it right every time all the time But you have seen the results I have changed my life Now my focus is YOU 🫵 I want to CHANGE lives I have changed many lives There is no feeling like it And I’m here to do it again I wish each one of you reading this a successful new year, and beyond ❤️ $MIRA $LFWD $WOLF $VOR $BMNR see you all on Monday!
1 · Reply
SadyK189
SadyK189 Jul. 5 at 11:28 PM
Top Stocks to watch next week 1 / 2: $SONN $VOR $WOLF $BMNR $IPA SONN: Looking good on daily chart. Key support at 2.80 - 3.10. Next key level to test is 5.15 - 5.45. Currently at 4.48. VOR: Kept posting about it regularly. Still looking good on daily chart. Key support at 1.35 - 1.50. Next key level to test is 2.25 - 2.50. WOLF: Looking good on 4hours chart. Key support at 0.91 -0.95. Next key level to test is 1.5 - 1.65. Currently at 1.16 BMNR: Initially alerted at 47. It's at 121 now. Still looking strong on 4hours chart. Key support at 81 - 86. Next key level to test is 160 - 180. IPA: Initially alerted at 0.82. Looking good on daily chart. Key support at 0.95 - 1.05. Next key level to test is 1.6 - 1.75.
2 · Reply
TALENT_ON_LOAN_FROM_GOD
TALENT_ON_LOAN_FROM_GOD Jul. 5 at 10:37 PM
$AEBI $BMNR $MIRA $VOR $WOLF ———-MIRA SHOULD BE $10 IMHO JUST OFF THE “SKNY MERGER ALONE”
1 · Reply
blackpearl1
blackpearl1 Jul. 5 at 6:12 PM
$VOR I hate long weekends. So anticipated to see $2+ at open Monday morning. What do you think this could do long term? Jan 2026.
1 · Reply
View2021
View2021 Jul. 4 at 6:32 PM
$VOR holding till we cross $7
1 · Reply
StockScanners
StockScanners Jul. 4 at 4:26 PM
$VOR Keep watch if this holds above 1.5
0 · Reply